Business · 19/10/2026
Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer
Mabwell, a biopharmaceutical company, will present Phase II clinical data on its Nectin-4-targeting ADC 9MW2821 for ADC-pretreated triple-negative breast cancer patients, following its presentation at the ESMO 2026 conference